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The management of renal cell carcinoma has undergone 
major transformation in recent years. With the onset of 
innovative surgical treatments and systemic medications 
– there has been an overall decrease in mortality.1 The 
systemic medications that target the vascular endothelial 
growth factor (VEGF) protein have created the most 
potent effects, especially when treating metastatic renal 
cell carcinoma. These prove to be important treatments 
since renal cell carcinoma has become the seventh 
most common cancer in men, with a general prevalence 
of 2-3%.2 With more advancement in knowledge about 
renal cell carcinoma, research has shown the utility of 
pazopanib (Votrient), a specific tyrosine kinase inhibitor, 
targeting multiple receptors; its action is primarily to 
block angiogenesis and tumor growth, such as VEGFR-1, 
VEGFR-2, VEGFR-3, PDGFR-A, PDGFR-B, FGFR-1, and 
FGFR-3.3 Targeting these specific receptors helps 
pazopanib to achieve an overall clinical benefit rate of 
greater than 90%, creating long-lasting disease control 
for patients 4
CaSE PrESEnTaTIon
A 63 year old Caucasian female with a past medical 
history of migraine headaches, dyslipidemia and 
depression was diagnosed with clear cell type Renal 
Cell Cancer, in late 2004. She underwent a laparoscopic 
nephrectomy in 2005 and a kidney mass measuring 9 x 
7 x 4 cm was removed, revealing T2 disease with Furman 
Grade 2 disease. The patient was followed for years and 
had a CT scan of her Chest in June of 2012 - where 
multiple bilateral pulmonary nodules were identified, the 
largest nodule was a 1.5 x 1.2 cm nodule at the right 
middle lobe. CT-guided biopsy was attempted, however 
was not diagnostic. Therefore, the patient underwent a 
right upper lobe wedge resection in October of 2012, 
which confirmed metastatic renal cell cancer to the 
lung. A PET/CT scan was also performed, and ruled out 
any evidence of abdominal or bone metastatic disease.
Additional therapeutic options were discussed with 
the patient, such as high-dose interleukin-2 infusion 
to achieve durable remission and then potentially start 
targeted therapy when needed. At the time when she 
was diagnosed with metastatic disease, the patient 
was in optimal health and was an excellent candidate 
for high-dose interleukin-2 treatment because she only 
had pulmonary nodules, without evidence of metastatic 
disease elsewhere in her body. She was agreeable and 
finished three cycles of high-dose interleukin-2 treatment 
along with Stereotactic Body Radiation Therapy. The 
patient was finally started on targeted therapy with a 
multi-tyrosine kinase inhibitor in June of 2013. Pazopanib 
400mg daily was started and titrated up to 600mg 
daily, which is considered optimal therapy. However, 
this patient began to have significant diarrhea without 
relief from Lomotil and other antidiarrheal medication 
regimens. Her dose was decreased to 400mg daily 
which resulted in a decreased amount of diarrhea - one 
to two times a day which was tolerable. Additionally, a 
few months after the onset of pazopanib treatment, the 
patient began having blurry vision, a symptom which 
was very worrisome.
dIFFErEnTIal dIagnoSIS 
The patient’s blurry vision was the main symptom of 
concern – her vision had been gradually worsening 
since the start of pazopanib therapy. Therefore, it was 
suspected that the systemic therapy was a plausible 
causal agent of the blurry vision. Upon visiting the ophthal-
mologist, she was diagnosed with Rhegmatogenous 
Retinal Tear OD. Her past ocular history was negative 
for any prior chronic diseases. On exam, the patient had 
retinal detachment, superotemporal (horseshoe) tear. 
Furthermore, the patient's left eye exam was remarkable 
for nuclear sclerosis. It was likely determined that the 
pazopanib caused a tear in the retina, thus further 
leading to detachment
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ouTCoME and Follow-uP 
To treat the pazopanib induced retinopathy, the patient 
had a pneumatic retinopexy performed on August 
19, 2014 and was started on Maxitrol 0.1% 1 drop OD, 
four times a day. Post operatively, she had decreased 
complaints of blurry vision. However, because of this 
adverse event along with intractable diarrhea, the 
patient was switched from pazopanib to Sutent 37.5mg 
daily. The Patient is currently doing well – the blurry 
vision has not worsened and is slowly improving after 
stopping pazopanib.
dISCuSSIon 
The usage of pazopanib is a common treatment in 
metastatic renal cell carcinoma. A multitude of studies 
have shown that “pazopanib demonstrated significant 
improvements in progression-free survival and response 
rate compared with placebo in patients with advanced 
or metastatic RCC.”7 Furthermore during these studies, 
there were no reports of patients developing other 
systemic abnormalities; the medication demonstrated 
acceptable safety and tolerability. However, as 
pazopanib is an oral angiogenesis inhibitor targeting 
specifically VEGF receptor, it is important to evaluate 
other locations in the body that might be affected 
secondary to inhibiting VEGF receptors.
A recent study was published evaluating the ocular 
effects of Sorafenib – as it was shown that many cancer 
signaling molecules, such as VEGF, were also expressed 
in ocular tissue.5,6 Sorafenib and Pazopanib have similar 
pathways, both specifically targeting VEGF proteins and 
thus both affecting the ocular tissue. Furthermore, there 
have been studies analyzing the effect of pazopanib in 
mice retinal tissues – specifically studying pazopanib’s 
effect on inhibiting choroidal neovascularization. It was 
shown that pazopanib primarily down-regulates the 
VEGF release in the retina and impairs VEGF-induced 
signaling and chemotaxis.8  Thus, a clear link is illustrated 
between pazopanib and its effect on retinal tissue. 
Furthermore, studies have shown that if pazopanib is 
“orally administered, [it] has good bioavailability to the 
retina/choroid” further giving proof to its profound 
effect on the retina and likely impact on treating ocular 
abnormalities, such as choroidal neovascularization by 
inhibiting angiogenesis.9,10
However, analysis of the link between pazopanib and 
retinal tears is important to be determined – in order 
to understand the findings in this case. Case reports of 
retinal effects from Sorafenib have been reported, likely 
secondary to a similarity between the VEGF receptors 
targeted in systemic RCC and in ocular tissue; similarly 
a comparison can be drawn between pazopanib and 
its effects on ocular tissues. With pazopanib’s large 
bioavailability in ocular tissues, and its direct effect on 
VEGF receptors – there can be a correlation made 
between pazopanib and retinal tears developing after 
initiating chemotherapy. Retinal tears occur when 
the retinal tissue begins to peel away from supporting 
tissue. Rhegmatogenous retinal detachment, the type 
of retinal attachment the patient in above case had, 
occurs primarily when a small retinal tear allows for fluid 
to pass from vitreous space into subretinal space where 
the retinal pigment epithelium (RPE) is located. Studies 
have illustrated that these tears are often preceded 
by anti-VEGF therapy, stating that an “increased risk 
of developing a retinal pigment epithelium tear after 
anti-VEGF therapy” is common in many patients.11  This 
occurs because following the administration of anti-VEGF 
therapy, there is rapid involution and contraction of the 
neovascular tissue that is attached to the undersurface of 
the retinal pigment epithelium. Those forces will cause a 
contractile force of the RPE forcing a tear on the retinal 
tissue.12  Given the pathophysiology of retinal tears and 
its relationship with anti-VEGF therapy – it is highly 
probable that the repeated administration of pazopanib 
in therapeutic doses for RCC can lead to strain of the 
retinal pigment epithelium, inducing a tear and further 
progressing onto a rhegmatogenous retinal detachment.
KEy PoInTS 
This case illustrates a risk with using VEGF inhibitors, 
such as pazopanib, due to the possibility of retinal 
damage causing tears leading to detachment. As in our 
case, there is an increased amount of anti-VEGF being 
used in renal cell carcinoma cases at therapeutic doses. 
With the increased usage, guidelines may be required 
for annual ophthalmology screening to monitor for 
retinal abnormalities. Furthermore, follow up will be 
required to determine if discontinuing the pazopanib 
and starting Sutent helped deter further ocular 
abnormalities. Overall, it should be recommended to 
discontinue pazopanib if any blurry vision or vision 
changes are noted. 
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